Sanofi India Ltd reported an 8% growth in net sales for Q3 2024, with an operating profit increase from INR 104 crores in Q3 2023 to INR 110 crores in Q3 2024, following the demerger of its consumer healthcare business. The Board also approved a review of the companys office space, considering a possible sale or relocation after the demerger.